264254-32-2

Upstream product

• 108-30-5 succinic acid anhydride 
• 127-40-2 lutein 

Downstream Products

• 1355481-26-3 C₈₀H₁₂₈O₂₄ 
• 1355481-68-3 C₆₄H₉₆O₁₆ 

Relevant academic research and scientific papers

Synthesis of lutein esters using a novel biocatalyst of: Candida antarctica lipase B covalently immobilized on functionalized graphitic carbon nitride nanosheets

Lutein scavenges free radicals and inhibits vision damage caused by photo oxidation, while decomposing easily with light and heat. Its stability and bioavailability can be tremendously improved by lutein ester synthesis. However, green and efficient ester

SMALL MOLECULE COMPOUNDS TO SUPPORT HEALTHY HUMAN AGING

Disclosed herein are methods of activating expression of the FOXO3 gene in a subject comprising administering to a subject small molecule compound (such as astaxanthin and/or one or more astaxanthin derivatives), or pharmaceutically acceptable salts there

Dicarotenoid esters of bivalent acids

For the evaluation of the synthesis of dendritic esters from carotenoids the C20 apocarotenoid retinol was chosen for model studies, being a commercially available hydroxy carotenoid. Dimers were synthesized from retinol with dicarboxyl cores and from retinol succinate with other hydroxy carotenoids.

Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof

Administering water-soluble or dispersible synthetic analogs or derivatives of astaxanthin, lutein, zeaxanthin, or lycophyll and/or other carotenoids to a subject may reduce some of the adverse effects of inflammation in a body organ or tissue. The analogs or derivatives may be incorporated into pharmaceutical, over-the-counter, or nutraceutical preparations. Administration of the analogs or derivatives described herein may reduce deposition of inflammatory mediators such as C-reactive protein, complement system proteins or the membrane attack complex (MAC) in tissues. Reduced deposition of these molecules in tissues may reduce cell damage and/or lysis in the tissues.

CAROTENOIDS, CAROTENOID ANALOGS, OR CAROTENOID DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS

A method and system used for treating proliferative disorders using carotenoids, carotenoid analogs, and/or carotenoid derivatives. The method and system may be used for chemoprevention and/or chemotherapy. The method and system may induce apoptosis in target cells, tissues, and/or organs. The analog, derivative, or intermediate may be administered to a cell, a group of cells, a tissue, an organ or a subject, such that at least a portion of the undesirable consequences of the proliferative disorder are thereby reduced.

Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of visual disabilities

A method and system used for treating visual disabilities using carotenoids, carotenoid analogs, and/or carotenoid derivatives. The analog, derivative, or intermediate may be administered such that a subject's risk of experiencing diseases associated with visual disabilities may be thereby reduced. Analogs or derivatives of carotenoids may include substituents including for example co-antioxidants (e.g., Vitamin C and Vitamin C analogs). The carotenoid analog or derivative may be synthetic. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include an acyclic alkene including at least one substituent and/or a cyclic ring including at least one substituent. In some embodiments, a carotenoid analog or derivative may include at least one substituent. The substituent may enhance the solubility of the carotenoid analog or derivative such that the carotenoid analog or derivative at least partially dissolves in water.